NVST
Healthcare · Medical Instruments & Supplies
Performance
NVST (NVST) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
NVST (NVST) operates in the Medical Instruments & Supplies space within the Healthcare sector. With a market cap of $4.0B, it qualifies as a small-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.
- Forward P/E (15.8×) is lower than trailing P/E (60.6×) — analysts expect earnings to improve
- Revenue growth of 14% YoY shows solid business momentum
- Earnings grew 130% YoY — bottom-line is expanding fast
- Current ratio of 2.4× — ample short-term liquidity
- High P/E of 60.6× implies high expectations already priced in — leaves little room for disappointment
- Thin profit margin of 2.4% — little buffer against cost increases
- High debt-to-equity of 51.61× increases financial risk, especially with elevated interest rates
- No dividend history — total return depends entirely on price appreciation
Verdict
Hold
Mixed signals — strengths and risks roughly balance. Wait for a clearer catalyst.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Related Articles
Revenue & Results
Dividends
This stock does not pay dividends.
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Earnings
Next Earnings
Aug 5, 2026
50
days
EPS (TTM)
$0.41
P/E (TTM)
60.6
Fwd P/E
15.8
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Key Statistics
Valuation
Trading
Dividends
Profitability
Balance Sheet
Fair Value Estimates
Current price: $24.83
Graham Number
√(22.5 × EPS × Book Value)
$13.21
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
N/A
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
5/10
63% score
Pays dividends
No dividend history found
Dividend consistency (5Y+)
Uninterrupted dividend payments for at least 5 years
ROE above 10%
2.2%Return on equity — measures how efficiently capital is used
Positive profit margin
2.4%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+14.4%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+130.0%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
51.61×Low financial leverage reduces risk of distress
Current ratio above 1
2.44×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$73M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
Stock must distribute income to shareholders
Related Assets
Healthcare
About NVST
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Location
Brea, United States
Employees
12,000